![Christopher Haqq](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christopher Haqq
Technik-/Wissenschafts-/F&E-Leiter bei
ELICIO THERAPEUTICS, INC.
Vermögen: 125 046 $ am 30.06.2026
Profil
Christopher M.
Haqq currently works at Elicio Therapeutics, Inc., as Chief Medical Officer & Executive Vice President from 2019.
Dr. Haqq also formerly worked at Consonance-HFW Acquisition Corp., as Independent Director from 2020 to 2021, Amgen, Inc., as Manager-Early Development Oncology Group, Cougar Biotechnology, Inc., as Vice President-Clinical Research & Development from 2007 to 2009, The University of California, San Francisco, as Assistant Professor, Janssen Oncology, Inc., as Vice President-Clinical Research & Development from 2007 to 2011, Atara Biotherapeutics, Inc., as Chief Scientific Officer, Executive VP-R&D from 2012 to 2019, and Elicio Therapeutics, Inc. (United States), as Chief Medical Officer & Executive Vice President from 2019 to 2023.
Dr. Haqq received his undergraduate degree from Stanford University and doctorate degree from Harvard Medical School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ELICIO THERAPEUTICS, INC 0,17 % | 09.04.2026 | 31.981 ( 0,17 % ) | 125 046 $ | 30.06.2026 |
Aktive Positionen von Christopher Haqq
| Unternehmen | Position | Beginn |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2019 |
Ehemalige bekannte Positionen von Christopher Haqq
| Unternehmen | Position | Ende |
|---|---|---|
Elicio Therapeutics, Inc. (United States)
 Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2023 |
| SURROZEN, INC. | Direktor/Vorstandsmitglied | 01.04.2021 |
| ATARA BIOTHERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 25.10.2019 |
Janssen Oncology, Inc.
 Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2011 |
Cougar Biotechnology, Inc. /Old/
 Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Technik-/Wissenschafts-/F&E-Leiter | 13.07.2009 |
Ausbildung von Christopher Haqq
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
38
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Health Technology |
Elicio Therapeutics, Inc. (United States)
Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Janssen Oncology, Inc.
Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Health Technology |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
 Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Consonance-HFW Acquisition Corp.
 Consonance-HFW Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Elicio Therapeutics, Inc.
 Elicio Therapeutics, Inc. BiotechnologyHealth Technology Develops cancer immunotherapies | Health Technology |
Wählen Sie MarketScreener 
